Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Mr. Glenn P. Brame

Chief Technical Operations Officer

Ms. Betty Jean Swartz

Chief Business Officer

Mr. Eric J. Warren R.Ph.

Chief Commercial Officer

Dr. JoAnne Micale Foody FACC, M.D.

Chief Medical Officer

Mr. Sheldon L. Koenig

President, Chief Executive Officer & Director

Mr. Benjamin O. Looker

General Counsel

Mr. Benjamin  Halladay M.B.A.

Chief Financial Officer

Tiffany  Aldrich M.B.A.

Associate Director of Corporate Communications

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. Structura de conducere

Informații despre conducere